39 Thus, combination therapy targeting CIB1 may prove to be a safe and durable strategy for treating triple-negative breast cancer and potentially other cancers.39 Our research highlights the value of CIB1 blockade as an effective candidate to overcome HCC resistance to lenvatinib. The gene discussed is CIB1; the disease is hepatocellular carcinoma.